Amyotrophic Lateral Sclerosis: Current and Future Treatment Strategies

Drugs

Volumn 51, Issue 1, 1996, Pages 28-44

  Festoff, Barry W ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ANGIOTENSIN; ANGIOTENSINOGEN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRANCHED CHAIN AMINO ACID; CALCIUM ANTAGONIST; CILIARY NEUROTROPHIC FACTOR; CYCLOSPORIN; DEXTROMETHORPHAN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LAMOTRIGINE; NEURITE PROMOTING FACTOR; NEUROTROPHIC FACTOR; PROTEASE NEXIN I; RECOMBINANT SOMATOMEDIN C; RILUZOLE; SELEGILINE;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; AUTOSOMAL DOMINANT INHERITANCE; BREATHING MUSCLE; CELL DEATH; CHILL; CLINICAL TRIAL; DRUG FATALITY; FEVER; HUMAN; INTELLECT; MOTOR NEURON DISEASE; MUSCLE ATROPHY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOGENESIS; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SYNAPSE;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CILIARY NEUROTROPHIC FACTOR; CLINICAL TRIALS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NERVE TISSUE PROTEINS; RILUZOLE; THIAZOLES;

EID: 0030029277     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651010-00004     Document Type: Review

References (120)

1. Tandan R, Bradley WG. Amyotrophic lateral sclerosis: part I. Clinical features, pathology, and ethical issues in management. Ann Neurol 1985; 18: 271-80
2. Festoff BW. Amyotrophic lateral sclerosis: the syndrome, its pathophysiology and approach to treatment. In: Davidoff RA, editor. The spinal cord. New York: Marcel Dekker, Inc., 1987: 607-64
3. Ringel SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993; 43: 1316-22
4. Festoff BW, Perurena OH, Singer PA. 'Untreatable' neuromuscular disease: treatment trials and symptomatic treatment of amyotrophic lateral sclerosis. J Kans Med Soc 1983; 84: 312-7
5. Norris F, Shepherd R, Denys E, et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 1993; 118: 48-55
6. Askmark H, Aquilonius S-M. Amyotrophic lateral sclerosis: practical treatment recommendations. CNS Drugs 1994; 2: 102-9
7. Festoff BW. Protocol for a model therapeutic trial in amyotrophic lateral sclerosis. In: Rose FC, editor. Research progress in motor neurone disease. London: Pitman, 1984: 432-42
8. Munsat TL, Hollander D, Andres P, et al. Clinical trials in ALS: measurement and natural history. Adv Neurol 1991; 56: 515-9
9. Pradas J, Finison L, Andres PL, et al. The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology 1993; 43: 751-5
10. Brooks BR, Sufit RL, DePaul R, et al. Design of clinical therapeutic trials in amyotrophic lateral sclerosis. Adv Neurol 1991; 56: 521-46
11. Subcommittee on Motor Neuron Diseases WRGoND. Airlie House guidelines: therapeutic trials in amyotrophic lateral sclerosis. J Neurol Sci 1995; 129: 1-10
12. Charcot JM. Sclérose des cordons latéraux de la moelle épinière chez femme hystérique atteinte de contracture permanente des quatre membres. Bull Soc Med Hop Paris 1865; 2: 24-42
13. Charcot JM, Joffroy A. Deux cas d'atrophie musculaire progressive avec lesions de la substance grise et des faisceaux antériolatéraux de la moelle épinière. Arch Physiol Norm Pathol 1869; 2: 354-67; 629-49; 744-60
14. Greene LA, Shooter EM. The nerve growth factor: biochemistry, synthesis, and mechanism of action. Ann Rev Neurosci 1980; 3: 353-402
15. Lindsay RM, Alderson RF, Friedman B, et al. The neurotrophin family of NGF-related neurotrophic factors. Restorative Neurol Neurosci 1991; 2: 211-20
16. Hempstead BL, Martinzanca D, Kaplan DR, et al. High-affinity NGF binding requires coexpression of the Trk proto-oncogene and the low-affinity NGF receptor. Nature 1991; 350: 678-83
17. Ip NY, Maisonpierre P, Alderson R, et al. The neurotrophins and CNTF: specificity of action towards PNS and CNS neurons. J Physiol Paris 1991; 85: 123-30
18. Lin LF, Mismer D, Lile JD, et al. Purification, cloning and expression of ciliary neurotrophic factor (CNTF). Science 1989; 246: 1023-5
19. Abraham JA, Whang JL, Tumolo A, et al. Human basic fibroblast growth factor: nucleotide sequence and genomic organization. EMBO J 1986; 5: 2523-8
20. Rubin LL, Philpott KL, Brooks SF. Apoptosis: the cell cycle and cell death. Curr Biol 1993; 3: 391-4
21. Bowen ID. Apoptosis or programmed cell death. Cell Biol Int Rep 1993; 17: 365-80
22. Williams GT, Smith CA. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993; 74: 777-9
23. Johnson Jr EM, Deckwerth TL. Molecular mechanisms of developmental neuronal death. Annu Rev Neurosci 1993; 16: 31-46
24. Hamburger V. History of the discovery of neuronal death in embryos. J Neurobiol 1992; 23: 1116-23
25. Levi-Montalcini R. The nerve growth factor: its mode of action on sensory and sympathetic nerve cells. Harvey Lect 1966; 60: 217-59
26. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987; 237: 1154-62
27. Oppenheim RW. Cell death during development of the nervous system. Annu Rev Neurosci 1991; 14: 453-501
28. Lowrie MB, Vrbová G. Dependence of postnatal motoneurones on their targets: review and hypothesis. Trends Neurosci 1992; 15: 80-4
29. Ellis H, Horvitz H. Genetic control of programmed cell death in the nematode C. elegans. Cell 1986; 44: 817-29
30. Yuan J, Horvitz H. The Caenorhabitis elegans genes ced-3 and ced-4 act cell autonomously to cause programmed cell death. Dev Biol 1990; 138: 33-41
31. Kumar S. ICE-like proteases in apoptosis. Trends Biochem Sci 1995; 20: 198-202
32. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995; 376: 37-43
33. Quan LT, Caputo A, Bleackley RC, et al. Granzyme B is inhibited by the cowpox virus serpin cytokine response modifier A. J Biol Chem 1995; 270: 10377-9
34. Gagliardini V, Fernandez PA, Lee RK, et al. Prevention of vertebrate neuronal death by the crmA gene. Science 1994; 263: 826-8
35. Festoff BW. Neuromuscular junction macromolecules in the pathogenesis of amyotrophic leteral sclerosis. Med Hypotheses 1980; 6: 121-31
36. Festoff BW, Hantaï D, Soria J, et al. Plasminogen activator in mammalian skeletal muscle: characteristics of effect of denervation on urokinase-like and tissue activator. J Cell Biol 1986; 103: 1415-21
37. Festoff BW, Rao JS, Hantaï D. Plasminogen activators and inhibitors in the neuromuscular system: III. The serpin protease nexin I is synthesized by muscle and localized at neuromuscular synapses. J Cell Physiol 1991; 147: 76-86
38. Festoff BW. Protease cascade dysregulation and synaptic degeneration in amyotrophic lateral sclerosis. In: Smith RA, editor. Handbook of amyotrophic lateral sclerosis. New York: Marcel Dekker. 1992: 661-85
39. Sasaki S, Maruyama S. Synapse loss in anterior horn neurons in amyotrophic lateral sclerosis. Acta Neuropathol 1994; 88: 222-7
40. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990; 27: 457-64
41. Scheff SW, Sparks DL, Price DA. Quantitative assessment of synaptic density in the entorhinal cortex in Alzheimer's disease. Ann Neurol 1993; 34: 356-61
42. Scheff SW, Price DA. Synapse loss in the temporal lobe in Alzheimer's disease. Ann Neurol 1993; 33: 190-9
43. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-80
44. Monard D, Suidan HS, Nitsch C. Relevance of the balance between glia-derived nexin and thrombin following lesion in the nervous system. Ann NY Acad Sci 1992; 674: 237-42
45. Monard D. Tinkering with certain blood components can engender distinct functions in the nervous system. Perspect Dev Neurobiol 1993; 1: 165-8
46. Seeds NW, Verrall S, Friedman G, et al. Plasminogen activators and plasminogen activator inhibitors in neural development. Ann NY Acad Sci 1992; 667: 32-40
47. Bilak M, Askanas V, Engel WK. Strong immunoreactivity of α1-antichymotrypsin co-localizes with β-amyloid protein and ubiquitin in vacuolated muscle fibers of inclusion-body myositis. Acta Neuropathol 1993; 85: 378-82
48. Akaaboune M, Ma J, Festoff BW, et al. The influence of denervation on beta-amyloid protein precursor and alpha 1-anti-chymotrypsin in mouse skeletal muscle. Neuromuscul Disord 1993; 3: 477-81
49. 1-anti-chymotrypsin as revealed by axotomy. J Neurobiol 1994; 25: 503-14
50. Oltersdorf T, Fritz LC, Schenk DB, et al. The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II. Nature 1989; 341: 144-7
51. McMahan UJ. The agrin hypothesis. Cold Spring Harb Symp Quant Biol 1990; 55: 407-18
52. Festoff BW Crigger NJ. Therapeutic trials in amyotrophic lateral sclerosis: a review. In: Mulder DM, editor. Amyotrophic lateral sclerosis: diagnosis and treatment. Boston: Houghton Mifflin. 1980: 337-66
53. Siddique T, Figlewicz D, Pericak-Vance MA, et al. Assignment of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence for genetic heterogeneity. N Engl J Med 1991; 324: 1381-4
54. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62
55. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a humun Cu,Zn superoxide dismutase mutation. Science 1994; 264: 1772-5
56. Lilienfeld DE, Perl DP. Projected neurodegenerative disease mortality in the United States. 1990-2040. Neuroepidemiology 1993; 12: 219-28
57. Barinaga M. Neurotrophic factors enter the clinic. Science 1994; 264: 772-4
58. McKhann GM. Clinical trials in a changing era. Ann Neurol 1994; 36: 683-7
59. Rowland LP. Amyotrophic lateral sclerosis: theories and therapies. Ann Neurol 1994; 35: 129-30
60. Bensimon G, Lacomblez L, Meininger V, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585-91
61. Lai EC, Felice K, Festoff BW, et al. Efficacy of recombinant human insulin-like growth factor I in the treatment of amyotrophic lateral sclerosis: a double-blind, placebo-controlled study. New Engl J Med. In press
62. Winkler J, Thal LJ. Clinical and potential of growth factors in neurological disorders. CNS Drugs 1994; 2: 465-78
63. Thoenen H. The changing scene of neurotrophic factors. Trends Neurosci 1991; 14: 165-70
64. Hefti F, Hartikka J, Knusel B. Function of neurotrophic factors in the adult and aging bain and their possible use n the treatment of neurodegenerative diseases. Neurobiol Aging 1989; 10: 515-33
65. Lewis ME, Neff NT, Contreras PC, et al. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol 1993; 124: 73-88
66. Hagg T, Varon S. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc Natl Acad Sci USA 1993; 90: 6315-9
67. Patterson PH, Nawa H. Neuronal differentiation factors/ cytokines and synaptic plasticity. Cell 1993; 72: 123-37
68. Arakawa Y, Sendtner M, Thoenen H. Survival effect of ciliary neurotrophic factor (CNTF) on chick embryonic motoneurons in culture: comparison with other neurotrophic factors and cytokines. J Neurosci 1990; 10: 3507-15
69. Magal E, Burnham P, Varon S. Effects of ciliary neurotrophic factor on rat spinal cord neurons in vitro: survival and expression of choline acetyltransferase and low-affinity nerve growth factor receptors. Dev Brain Res 1991; 63: 141-50
70. Sendtner M, Kreutzberg GW, Thoenen H. Ciliary neurotrophic factor prevents the degeneration of motor neurons after axotomy. Nature 1990; 345: 440-1
71. Group ACTSAPI-IS, Brooks BR, Sanjak M, et al. Recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis (ALS) patients: phase 1-1 safety, tolerability and pharmacokinetic studies. Neurology 1993; 43: A416
72. Brooks BR, Group ACTSAPI-IS. Recombinant human, ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis (ALS) patients: dose selection strategy in Phase I-II safety, tolerability and pharmacokinetic studies. XVth World Congress of Neurology. Vancouver, September 1993
73. Jeyarajah DR, Thistlethwaile Jr JR. General aspects of cytokine-release syndrome: timing and incidence of symptoms. Transplant Proc 1993; 25 Suppl. 1: 16-20
74. Murakami M, Hibi M, Kakagawa N, et al. IL-6-induced homodimerization of gp 130 and associated activation of a tyrosine kinase. Science 1993; 260: 1808-10
75. Campbell IL, Abraham CR, Masliah E, et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA 1993; 90: 10061-5
76. Zapf J, Froesch ER. Insulin-like growth factor/somatomedins: structure, secretion, biological actions and physiological role. Horm Res 1986; 24: 121-30
77. Smith RA, Melmed S, Sherman B, et al. Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle Nerve 1993; 16: 624-33
78. Neff NT, Prevette D, Houenou LJ, et al. Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J Neurobiol 1993; 24: 1578-88
79. Krieger C, Lai R, Mitsumoto H, et al. The wobbler mouse: quantitative autoradiography of glutamatergic ligand binding sites in spinal cord. Neurodegeneration 1993; 2: 9-17
80. Hantaï D, Akaaboune M, Lagord C, et al. Beneficial effects of insulin-like growth factor I on wobbler mouse motoneuron disease. J Neurolog Sci 1995; 129 Suppl. 122-6
81. Festoff BW, Yang SX, Vaught J, et al. The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies. J Neurol Sci 1995; 129: 122-9
82. Shimasaki S, Ling N. Identification and molecular characterization of insulin-like growth factor binding protein (IGF-1, -2, -3, -4, -5, and -6). Prog Growth Factor Res 1991; 3: 243-66
83. Crosby SR, Tsigos C, Anderton CD, et al. Elevated plasma insulin-like growth factor binding protein-1 levels in type I (insulin-dependent) diabetic patients with peripheral neuropathy. Diabetologia 1992; 35: 868-72
84. Ma J, Yang SX, Ho GJ, et al. Insulin-like growth factor binding protein-1 at mouse neuromuscular synapses. Synapse 1994; 17: 225-9
85. Ma J, Yang SX, Ho GJ, et al. Insulin-like growth factor binding protein-1 is pre-synaptic at mouse neuromuscular synapses and is transported in nerve. Neurochem Res 1994; 19: 1363-8
86. Appel V, Stewart SS, Smith G, et al. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987; 22: 328-33
87. Adem A, Ekblom J, Gillberg PG, et al. Insulin-like growth factor-I receptors in human spinal cord: changes in amyotrophic lateral sclerosis. J Neural Transm Gen Sect 1994; 97: 73-84
88. Strimberg I, Bjîrklund L, Johansson M, et al. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp Neurol 1993; 124: 401-12
89. Henderson CE, Phillips HS, Pollock RA, et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle [see comments]. Science 1994; 266: 1062-4 Issn: 0036-8075
90. Lin HY, Lodish HF. Receptors for the TGF-β superfamily: Multiple polypeptides and serine/threonine kinases. Trends Cell Biol 1993; 3: 14-9
91. Li L, Wu W, Lin L-FH, et al. Rescue of adult mouse motoneurons from injury-induced cell death by glial cell line-derived neurotrophic factor Proc Natl Acad Sci USA 1995; 92: 9771-5
92. Choi DW. Amyotrophic lateral sclerosis and glutamate - too much of a good thing? N Engl J Med 1992; 326: 1493-5
93. Beal MF. Mechanisms of excitotoxicity in neurologic diseases. FASEB J 1992; 6: 3338-44
94. Plaitakis A, Caroscio JT. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 1987; 22: 575-9
95. Plaitakis A. Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: a hypothesis. Ann Neurol 1990; 28: 3-8
96. Plaitakis A, Smith J, Mandeli J, et al. A pilot trial of branched chain amino acid treatment in amyotrophic lateral sclerosis. Lancet 1988; 1: 1015-8
97. Group TIAS. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? Neurology 1993; 43: 2466-70
98. Plaitakis A. Branched-chain amino acids in ALS [letter]. Neurology 1994; 44: 1982
99. Eisen A, Krieger C. Pathogenic mechanisms in sporadic amyotrophic lateral sclerosis. Can J Neurol Sci 1993; 20: 286-96
100. Eisen A, Stewart H, Schulzer M, et al. Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. Can J Neurol Sci 1993; 20: 297-301
101. Askmark H, Aquilonius S-M, Gillberg P-G, et al. A pilot trial of dextromethorphan in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1993; 56: 197-200
102. Festoff BW, editor. Serine proteases and serpins in the nervous system: roles in development and in malignant and degenerative disease. New York: Plenum Press, 1990
103. Houenou LJ, Turner PL, Li L, et al. A serine protease inhibitor, protease nexin I, rescues motoneurons from naturally occurring and axotomy-induced cell death. Proc Natl Acad Sci USA 1995; 92: 895-9
104. Smith-Swintosky VL, Zimmer S, Fenton JW, II, et al. Protease nexin-1 and thrombin modulate Ca2+ homeostasis and sensitivity to glucose deprivation-induced injury. J Neurosci 1995; 15: 5840-50
105. Vaughan PJ, Pike CJ, Cotman CW, et al. Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults. J Neurosci 1995; 15: 5389-401
106. Baker JB, Knauer DJ, Cunningham DD. Protease nexins: secreted protease inhibitors that regulate protease actions at and near the cell surface. In: Conn PM, editor. The receptors. New York: Academic Press, 1986: 153-72
107. McGrogan M, Kennedy J, Li M, et al. Molecular cloning and expression of two forms of human protease nexin 1. Biotechnology 1988; 6: 172-7
108. Liu Y, Fields RD, Fitzgerald S, et al. Proteolytic activity, synapse elimination, and the Hebb synapse. J Neurobiol 1994; 25: 325-35
109. Liu Y, Fields RD, Festoff BW, et al. Proteolytic action of thrombin is required for electrical activity-dependent synapse reduction. Proc Natl Acad Sci USA 1994; 91: 10300-4
110. Festoff BW, Brenneman DE. Inhibition of activity-dependent neuronal death: vasoactive intestinal polypeptide stimulates secretion of the neurotrophic serpin, protease nexin 1, from astrocytes. J Neurobiol. In press
111. Carter RE, Cerosaletti KM, Burkin DJ, et al. The gene for the serpin thrombin inhibitor (P17), protease nexin I, is located on human chromosome 2q33-q35 and on syntenic regions in the mouse and sheep genomes. Genomics 1995; 27: 196-9
112. Hentati A, Bejaoui K, Pericak-Vance MA, et al. Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35. Nature Genetics 1994; 7: 425-8
113. Bunnemann B, Fuxe K, Ganten D. The brain renin-angiotensin system - localization and general significance. J Cardiovasc Pharmacol 1992; 19: S51-S62
114. Bleuel A, De Gasparo M, Whitebread S, et al. Regulation of prolease nexin-1 expression in cultured Schwann cells is mediated by angiotensin II receptors. J Neurosci 1995; 15: 750-61
115. Aquilonius SM, Jossan SS, Ekblom JG, et al. Increased binding of 3H-L-deprenyl in spinal cords from patients with amyotrophic lateral sclerosis as demonstrated by autoradiography. J Neural Transm Gen Sect 1992; 89: 111-22
116. Appel SH, Smith RG, Engelhardt JI, et al. Evidence for autoimmunity in amyotrophic lateral sclerosis. J Neurol Sci 1994; 124 Suppl.: 14-9
117. Alexianu ME, Ho BK, Mohamed AH, et al. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1994; 36: 846-58
118. Alexianu ME, Mohamed AH, Smith RG, et al. Apoptotic cell death of a hybrid motoneuron cell line induced by immunoglobulins from patients with amyotrophic lateral sclerosis. J Neurochem 1994; 63: 2365-8
119. Drachman DB, Chaudhry V, Cornblath D, et al. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation (see comments). Ann Neurol 1994; 35: 142-50
120. Vessada R, Sagot Y, Kato AC. Quantitative comparison of the effects of neurotrophic factors on axotomized motoneurons in vivo. Eur J Neurosci 1995; 7: 108-15